Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for its 2015 licensed patent application, No. 2887841 entitled, “Cannabis Drug Detection Device”. The Company has been pursuing this original patent application since its filing on April 16, 2015. It should be noted that a notice of allowance from the CIPO does not constitute a grant of patent. The Company will report on future material developments regarding its “Cannabis Drug Detection Device” patent application with CIPO in due course.
Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug-screening devices that will detect THC- the psychoactive component of marijuana that causes impairment using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment.